5248242025-10-012025-12-315248242025-04-012025-12-315248242025-10-012025-12-31in-capmkt:OtherExpenses1Member5248242025-04-012025-12-31in-capmkt:OtherExpenses1Member5248242025-10-012025-12-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares524824BALPHARMANOTLISTEDINE083D01012BAL PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-02-112026-02-03INRLakhsQuarterlyThird quarterSingle segmentPHARMACEUTICLES2026-02-1117:00:002026-02-1118:15:00Declaration of unmodified opinion2025-10-012025-12-31UnauditedConsolidated87689700032620008801590004351060002043000060630001732410004850800032299000146606000862253000179060000179060000000179060000000179060000179060001779900010700000159209000101.121.12001.121.121. The above un-audited financial results of the Company have been reviewed by the audit committee and approved by the board of Directors as their respective meetings held on 11.02.2026. <BR> 2. The Consolidated financial results have been prepared in accordance with the Companies ( Indian Accountinng Standards ) Rules , 2015 ( IND-AS) prescribed under Section 133 of the Companies Act,2013, read with relavent rules issued thereunder and other recognised accounting practises and policies to the extent applicable. The unaudited consolidated financial results relates to Bal Pharma ltd, its subsidiaries , joint ventures and associates and are prepared by applying IND AS 110, consolidated financial statements and IND AS 28 " Investments in associates and joint ventures". <BR> 3. The Company has only one reportable segment i.e Pharmaceuticles. <BR> 4. Previous period figures have been regrouped/rearranged wherever considered necessary to confirm to the period presentation.2025-04-012025-12-31UnauditedConsolidated2275855000216430002297498000119830900078064000-79994000483992000127621000802130003821290002270334000271640000271640000000271640000000271640000271640002690100026300000159209000101.691.69001.691.69Other Expenses146606000Other Expenses382129000UnauditedtrueSSJNB & Cotrue2026-03-31